Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
25 mai 2021 16h01 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS)....
Saniona har genomfört en Forsknings- och Utvecklingsdag om bolagets pipelineprogram inom jonkanaler
20 mai 2021 14h30 HE
|
Saniona AB
PRESSMEDDELANDE 20 maj 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, genomförde en digital FoU-dag idag. Under evenemanget...
Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs
20 mai 2021 14h30 HE
|
Saniona AB
PRESS RELEASE May 20, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which it...
Saniona anordnar Forsknings- och Utvecklingsdag om hur expertis inom jonkanaler kan utnyttjas för att behandla sällsynta sjukdomar
12 mai 2021 08h00 HE
|
Saniona AB
PRESSMEDDELANDE 12 maj 2021 Det digitala evenemanget äger rum torsdagen 20 maj 2021, kl. 11.00 EDT / 17.00 CEST Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad...
Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases
12 mai 2021 08h00 HE
|
Saniona AB
PRESS RELEASE May 12, 2021 Virtual event will take place on Thursday, May 20, 2021, at 11:00 am EDT / 17:00 CEST Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare...
Imara Reports First Quarter 2021 Financial Results and Business Highlights
11 mai 2021 07h00 HE
|
Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics
10 mai 2021 08h30 HE
|
Gennao Bio
~ Financing Co-led by OrbiMed and Logos Capital to Support Advancement of Proprietary Gene Monoclonal Antibody Platform (GMAB) ~ ~ Stephen Squinto, Ph.D., Appointed Chief Executive Officer and...
Saniona lanserar ny videoserie för att belysa hur Prader-Willis syndrom och hypotalamisk fetma drabbar patienter och anhöriga
10 mai 2021 08h00 HE
|
Saniona AB
PRESSMEDDELANDE 10 maj 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, tillkännager idag videoserien ”Saniona’s Community Voices”,...
Saniona Launches New Video Series to Highlight the Impact of Prader-Willi Syndrome and Hypothalamic Obesity on Patients and Caregivers
10 mai 2021 08h00 HE
|
Saniona AB
PRESS RELEASE May 10, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced its “Saniona’s Community Voices” video series, which will...
ProQR Announces First Quarter 2021 Operating and Financial Results
06 mai 2021 07h00 HE
|
ProQR Therapeutics N.V.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022Positive data reported from the Phase 1/2 clinical trial of QR-421a for the...